Birdwatch Note
2024-10-04 11:11:46 UTC - NOT_MISLEADING
Notes are about Fenbendazole the Post is about Ivermectin. Personal experience and opinions on both drugs are that they are highly useful for combating cancer. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/
Written by 6A53A1E2EF2F48695BE26E7F23A5DAC3C5CB0C84DAD6B8B3FC7C0ACBBF9F70A3
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1841929008285409627
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1842160680830738682
- noteId - 1842160680830738682
- participantId -
- noteAuthorParticipantId - 6A53A1E2EF2F48695BE26E7F23A5DAC3C5CB0C84DAD6B8B3FC7C0ACBBF9F70A3
- createdAtMillis - 1728040306657
- tweetId - 1841929008285409627
- classification - NOT_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 1
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Notes are about Fenbendazole the Post is about Ivermectin. Personal experience and opinions on both drugs are that they are highly useful for combating cancer. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/
Note Ratings
| rated at | rated by | |
| 2024-10-04 17:04:24 -0500 | Rating Details | |
| 2024-10-04 13:58:20 -0500 | Rating Details | |
| 2024-10-04 13:29:27 -0500 | Rating Details | |
| 2024-10-04 12:47:05 -0500 | Rating Details | |
| 2024-10-04 12:43:23 -0500 | Rating Details | |
| 2024-10-04 12:40:01 -0500 | Rating Details | |
| 2024-10-04 12:24:16 -0500 | Rating Details | |
| 2024-10-04 12:22:06 -0500 | Rating Details | |
| 2024-10-04 12:05:47 -0500 | Rating Details | |
| 2024-10-04 10:32:44 -0500 | Rating Details | |
| 2024-10-04 10:29:02 -0500 | Rating Details | |
| 2024-10-04 10:14:18 -0500 | Rating Details | |
| 2024-10-04 09:51:05 -0500 | Rating Details | |
| 2024-10-04 09:43:18 -0500 | Rating Details | |
| 2024-10-04 09:29:50 -0500 | Rating Details | |
| 2024-10-04 09:29:31 -0500 | Rating Details | |
| 2024-10-04 09:26:32 -0500 | Rating Details | |
| 2024-10-04 09:00:14 -0500 | Rating Details | |
| 2024-10-04 08:57:32 -0500 | Rating Details | |
| 2024-10-04 08:19:34 -0500 | Rating Details | |
| 2024-10-04 08:05:16 -0500 | Rating Details | |
| 2024-10-04 08:01:38 -0500 | Rating Details | |
| 2024-10-04 07:16:31 -0500 | Rating Details | |
| 2024-10-04 07:12:34 -0500 | Rating Details | |
| 2024-10-04 06:55:36 -0500 | Rating Details | |
| 2024-10-04 06:53:28 -0500 | Rating Details | |
| 2024-10-04 06:35:24 -0500 | Rating Details | |
| 2024-10-04 06:34:53 -0500 | Rating Details | |
| 2024-10-04 06:29:31 -0500 | Rating Details | |
| 2024-10-04 06:19:18 -0500 | Rating Details | |
| 2024-10-07 08:47:13 -0500 | Rating Details | |
| 2024-10-06 16:26:47 -0500 | Rating Details | |
| 2024-10-04 10:05:02 -0500 | Rating Details | |
| 2024-10-04 09:55:02 -0500 | Rating Details | |
| 2024-10-04 08:46:02 -0500 | Rating Details | |
| 2024-10-04 08:30:50 -0500 | Rating Details | |
| 2024-10-04 07:53:01 -0500 | Rating Details | |
| 2024-10-04 23:19:42 -0500 | Rating Details | |
| 2024-10-04 13:39:04 -0500 | Rating Details | |
| 2024-10-04 13:35:34 -0500 | Rating Details | |
| 2024-10-04 11:59:55 -0500 | Rating Details | |
| 2024-10-04 11:42:41 -0500 | Rating Details | |
| 2024-10-04 10:44:10 -0500 | Rating Details | |
| 2024-10-04 10:12:12 -0500 | Rating Details | |
| 2024-10-04 09:12:23 -0500 | Rating Details | |
| 2024-10-04 08:03:04 -0500 | Rating Details | |
| 2024-10-04 07:33:26 -0500 | Rating Details | |
| 2024-10-04 06:53:19 -0500 | Rating Details | |
| 2024-10-04 06:22:45 -0500 | Rating Details | |
| 2024-10-05 06:40:23 -0500 | Rating Details | |
| 2024-10-05 01:41:37 -0500 | Rating Details | |
| 2024-10-04 21:10:44 -0500 | Rating Details | |
| 2024-10-04 12:37:50 -0500 | Rating Details | |
| 2024-10-04 12:16:27 -0500 | Rating Details | |
| 2024-10-04 10:06:15 -0500 | Rating Details | |
| 2024-10-04 09:31:14 -0500 | Rating Details |